Vulnerability of 125I-α-conotoxin MII binding sites to nigrostriatal damage in monkey

被引:99
作者
Quik, M
Polonskaya, Y
Kulak, JM
McIntosh, JM
机构
[1] Parkinsons Inst, Sunnyvale, CA 94089 USA
[2] Univ Utah, Dept Biol & Psychiat, Salt Lake City, UT 84112 USA
关键词
alpha-conotoxin MII; alpha; 3; nAChRs; 6; MPTP; monkeys; autoradiography; nigrostriatal system; dopamine; Parkinson's disease;
D O I
10.1523/JNEUROSCI.21-15-05494.2001
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Parkinson's disease, a neurodegenerative movement disorder characterized by selective degeneration of nigrostriatal dopaminergic neurons, affects similar to1% of the population over 50. Because nicotinic acetylcholine receptors (nAChRs) may represent an important therapeutic target for this disorder, we performed experiments to elucidate the subtypes altered with nigrostriatal damage in parkinsonian monkeys. For this purpose we used I-125-alpha -conotoxin MII (CtxMII), a relatively new ligand that identifies alpha3 and/or alpha6 subunits containing nAChR subtypes. In brain from untreated monkeys, there was saturable I-125-alpha -CtxMII binding to a single population of high-affinity nicotinic sites (K-d = 0.9 nM), primarily localized in the visual, habenula-interpeduncular, and nigrostriatal-mesolimbic pathways. Administration of the selective dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine resulted in damage to the nigrostriatal system and parkinsonism. Autoradiographic analysis showed that I-125-alpha -CtxMII sites were selectively reduced (greater than or equal to 99%) in the basal ganglia and that the lesion-induced decreases correlated well with declines in the dopamine transporter, a marker of dopaminergic neuron integrity. These findings may indicate that most or all of I-125-alpha -CtxMII-labeled nAChR subtypes in the basal ganglia are present on nigrostriatal dopaminergic neurons, in contrast to I-125-epibatidine sites. These data suggest that the development of ligands directed to nAChR subtypes containing alpha3 and/or alpha6 subunits may yield a novel treatment strategy for parkinsonian patients with nigrostriatal dopaminergic degeneration.
引用
收藏
页码:5494 / 5500
页数:7
相关论文
共 58 条
[1]  
Allen R. S., 1998, Society for Neuroscience Abstracts, V24, P1341
[2]  
[Anonymous], 1963, STEREOTAXIC ATLAS BR
[3]  
Arroyo-Jiménez MD, 1999, J NEUROSCI, V19, P6475
[4]   COMPARATIVE ALTERATIONS OF NICOTINIC AND MUSCARINIC BINDING-SITES IN ALZHEIMERS AND PARKINSONS DISEASES [J].
AUBERT, I ;
ARAUJO, DM ;
CECYRE, D ;
ROBITAILLE, Y ;
GAUTHIER, S ;
QUIRION, R .
JOURNAL OF NEUROCHEMISTRY, 1992, 58 (02) :529-541
[5]   Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disorders [J].
Balfour, DJK ;
Fagerstrom, KO .
PHARMACOLOGY & THERAPEUTICS, 1996, 72 (01) :51-81
[6]   Acute intermittent nicotine treatment produces regional increases of basic fibroblast growth factor messenger RNA and protein in the tel- and diencephalon of the rat [J].
Belluardo, N ;
Blum, M ;
Mudo, G ;
Andbjer, B ;
Fuxe, K .
NEUROSCIENCE, 1998, 83 (03) :723-740
[7]   ATTENUATION OF 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE-INDUCED NEUROTOXICITY BY TOBACCO-SMOKE [J].
CARR, LA ;
ROWELL, PP .
NEUROPHARMACOLOGY, 1990, 29 (03) :311-314
[8]   A new alpha-conotoxin which targets alpha 3 beta 2 nicotinic acetylcholine receptors [J].
Cartier, GE ;
Yoshikami, DJ ;
Gray, WR ;
Luo, SQ ;
Olivera, BM ;
McIntosh, JM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (13) :7522-7528
[9]   Brain nicotinic receptors:: structure and regulation, role in learning and reinforcement [J].
Changeux, JP ;
Bertrand, D ;
Corringer, PJ ;
Dehaene, S ;
Edelstein, S ;
Léna, C ;
Le Novère, N ;
Marubio, L ;
Picciotto, M ;
Zoli, M .
BRAIN RESEARCH REVIEWS, 1998, 26 (2-3) :198-216
[10]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099